COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial.


Journal

ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 08 07 2022
accepted: 25 10 2022
entrez: 24 3 2023
pubmed: 25 3 2023
medline: 25 3 2023
Statut: epublish

Résumé

Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19. Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression. Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status. 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.

Sections du résumé

Background UNASSIGNED
Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19.
Methods UNASSIGNED
Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression.
Findings UNASSIGNED
Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status.
Conclusion UNASSIGNED
1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.

Identifiants

pubmed: 36960350
doi: 10.1183/23120541.00317-2022
pii: 00317-2022
pmc: PMC10030059
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: P. Tymoszuk owns the Data Analytics as a Service data science enterprise and is (from May 2021 on) a freelance data scientist working in his own enterprise; he received honoraria for the statistical analysis of the CovILD study. All other authors have no conflict of interest related to this study to declare.

Références

Lancet Respir Med. 2021 Jan;9(1):107-116
pubmed: 33217366
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34244323
Radiology. 2022 Aug;304(2):462-470
pubmed: 35348379
Radiology. 2021 Oct;301(1):E353-E360
pubmed: 34032513
Elife. 2022 Feb 08;11:
pubmed: 35131031
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Psychosom Med. 2016 Jan;78(1):5-12
pubmed: 26461855
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Psychosom Res. 1998 Nov;45(5):411-7
pubmed: 9835234
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
Lancet. 2021 Feb 6;397(10273):455-457
pubmed: 33357467
Health Qual Life Outcomes. 2021 Mar 6;19(1):76
pubmed: 33676523
Open Forum Infect Dis. 2021 Jul 16;8(8):ofab384
pubmed: 34386546
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Thromb Haemost. 2021 Oct;19(10):2546-2553
pubmed: 34375505
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
ESC Heart Fail. 2021 Jun;8(3):2232-2239
pubmed: 33773099
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Stat Softw. 2017 Aug;79:
pubmed: 30686944
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Radiology. 2022 Mar;302(3):709-719
pubmed: 34609153
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
Sci Rep. 2021 Nov 22;11(1):22666
pubmed: 34811387
Respir Care. 2018 Jan;63(1):77-85
pubmed: 28874609
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Assessment. 2004 Mar;11(1):94-101
pubmed: 14994958
ERJ Open Res. 2022 Apr 11;8(2):
pubmed: 35415186

Auteurs

Sabina Sahanic (S)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Piotr Tymoszuk (P)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Data Analytics as a Service Tirol, Innsbruck, Austria.

Anna K Luger (AK)

Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.

Katharina Hüfner (K)

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital for Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.

Anna Boehm (A)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Alex Pizzini (A)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Christoph Schwabl (C)

Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.

Sabine Koppelstätter (S)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Katharina Kurz (K)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Malte Asshoff (M)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Birgit Mosheimer-Feistritzer (B)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Maximilian Coen (M)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Bernhard Pfeifer (B)

Division for Health Networking and Telehealth, Biomedical Informatics and Mechatronics, UMIT, Hall in Tyrol, Austria.

Verena Rass (V)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Alexander Egger (A)

Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria.

Gregor Hörmann (G)

Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria.

Barbara Sperner-Unterweger (B)

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital for Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.

Raimund Helbok (R)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Ewald Wöll (E)

Department of Internal Medicine, St Vinzenz Hospital, Zams, Austria.

Günter Weiss (G)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Gerlig Widmann (G)

Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.

Ivan Tancevski (I)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Thomas Sonnweber (T)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Judith Löffler-Ragg (J)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Classifications MeSH